Goldman Sachs has raised Novo Nordisk (NYSE: NVO) to Buy from Neutral; Charles River Laboratories (NYSE: CRL) downgraded to Neutral at Goldman Sachs.

JPMorgan has raised its rating on Invitrogen (NASDAQ: IVGN) to Overweight from Neutral.

Lazard Capital Markets started coverage of Aspenbio (NASDAQ: APPY) with a “Buy” rating.

R.W.Baird Downgraded Third Wave Technologies (NASDAQ: TWTI) to Neutral from Outperform.

Jon Ogg
June 24, 2008

This merger is one of the more interesting in medical and diagnostic companies, despite neither company being a household name.  Third Wave develops and markets molecular diagnostic reagents for a wide variety of DNA and RNA analysis applications for conditions such as Cystic Fibrosis, Hepatitis C, cardiovascular risk and other diseases.  Its HPV market opportunity is a $200 million market and growth in excess of 40% in each of the past five years. Hologic believes the global market for HPV testing will increase to $800 million in the next few years.

Third Wave shareholders will receive an aggregate amount of an estimated $580 million in cash, assuming the conversion of Third Wave’s outstanding convertible notes, warrants and restricted stock.   Hologic plans to finance this transaction with a $600 million loan in the form of a senior secured credit facility, and it has secured fully committed debt financing for the full consideration from Goldman, Sachs & Co.

Hologic expects the acquisition of Third Wave to help accelerate the growth of its diagnostics division, and once the pending FDA approval is granted it sees a higher diagnostic growth business for womens’ health.  The company noted “If and when Third Wave’s HPV tests receive FDA approval, which we hope will be in the first half of calendar 2009, we will be well-positioned to take these products quickly and effectively to market.”

The transaction should close in the third calendar quarter of 2008, and is expected to be modestly dilutive to Hologic’s adjusted earnings per share in the first full year after closing, and increasingly accretive thereafter.

It is expected to be slightly dilutive to Hologic’s non-GAAP EPS in Fiscal 2008 and it anticipates $0.02 to $0.03 per share dilution to previous guidance, excluding acquisition-related charges. The acquisition is expected to be approximately $0.10 dilutive to non-GAAP EPS in Fiscal 2009 and to be accretive to non-GAAP EPS beginning in Fiscal 2010.  The transaction is expected to be cash flow neutral in Fiscal 2009 as a result of the use of $160 million in acquired tax NOLs, including interest and financing expense of approximately $40 million from the term loan of approximately $600 million to finance the acquisition.

Jon Ogg
June 9, 2008

This merger is one of the more interesting in medical and diagnostic companies, despite neither company being a household name.  Third Wave develops and markets molecular diagnostic reagents for a wide variety of DNA and RNA analysis applications for conditions such as Cystic Fibrosis, Hepatitis C, cardiovascular risk and other diseases.  Its HPV market opportunity is a $200 million market and growth in excess of 40% in each of the past five years. Hologic believes the global market for HPV testing will increase to $800 million in the next few years.

Third Wave shareholders will receive an aggregate amount of an estimated $580 million in cash, assuming the conversion of Third Wave’s outstanding convertible notes, warrants and restricted stock.   Hologic plans to finance this transaction with a $600 million loan in the form of a senior secured credit facility, and it has secured fully committed debt financing for the full consideration from Goldman, Sachs & Co.

Hologic expects the acquisition of Third Wave to help accelerate the growth of its diagnostics division, and once the pending FDA approval is granted it sees a higher diagnostic growth business for womens’ health.  The company noted “If and when Third Wave’s HPV tests receive FDA approval, which we hope will be in the first half of calendar 2009, we will be well-positioned to take these products quickly and effectively to market.”

The transaction should close in the third calendar quarter of 2008, and is expected to be modestly dilutive to Hologic’s adjusted earnings per share in the first full year after closing, and increasingly accretive thereafter.

It is expected to be slightly dilutive to Hologic’s non-GAAP EPS in Fiscal 2008 and it anticipates $0.02 to $0.03 per share dilution to previous guidance, excluding acquisition-related charges. The acquisition is expected to be approximately $0.10 dilutive to non-GAAP EPS in Fiscal 2009 and to be accretive to non-GAAP EPS beginning in Fiscal 2010.  The transaction is expected to be cash flow neutral in Fiscal 2009 as a result of the use of $160 million in acquired tax NOLs, including interest and financing expense of approximately $40 million from the term loan of approximately $600 million to finance the acquisition.

Jon Ogg
June 9, 2008